Table 3.
Microbiological findings
| Derivation cohort | P value | Validation cohort | P value | |||
|---|---|---|---|---|---|---|
| VAT (n = 320) | VAP (n = 369) | VAT (n = 70) | VAP (n = 136) | |||
| Streptococcus pneumoniae | 16 (5%) | 24 (7%) | 0.41 | 2 (3%) | 5 (4%) | 1 |
| Stenotrophomonas maltophila | 19 (6%) | 12 (3%) | 0.09 | 4 (6%) | 6 (4%) | 0.74 |
| MRSA | 8 (2%) | 8 (2%) | 0.77 | 1 (1%) | 1 (1%) | 1 |
| MSSA | 66 (21%) | 80 (22%) | 0.73 | 6 (9%) | 21 (15%) | 0.17 |
| Serratia marcescens | 12 (4%) | 16 (4%) | 0.69 | 3 (4%) | 5 (4%) | 1 |
| Pseudomonas aeruginosa | 79 (25%) | 89 (24%) | 0.86 | 20 (29%) | 29 (21%) | 0.25 |
| Proteus mirabilis | 15 (5%) | 14 (4%) | 0.56 | 3 (4%) | 5 (4%) | 1 |
| Klebsiella pneumoniae | 48 (15%) | 53 (14%) | 0.81 | 9 (13%) | 30 (22%) | 0.11 |
| Haemophilus influenzae | 32 (10%) | 25 (7%) | 0.12 | 4 (6%) | 6 (4%) | 0.74 |
| Escherichia coli | 37 (12%) | 40 (11%) | 0.76 | 5 (7%) | 9 (7%) | 1 |
| Enterobacter spp. | 35 (11%) | 46 (12%) | 0.53 | 4 (6%) | 21 (15%) | 0.043 |
| Citrobacter freundii | 7 (2%) | 6 (2%) | 0.58 | 4 (6%) | 1 (1%) | 0.047 |
| Acinetobacter baumannii | 14 (4%) | 27 (7%) | 0.10 | 0 (0%) | 2 (1%) | 0.55 |
Data are presented as number (%) or mean (SD)
COPD Chronic obstructive pulmonary disease, MSSA Methicillin-sensitive Staphylococcus Aureus, MRSA Methicillin-resistant Staphylococcus Aureus, SAPS Simplified acute physiology score, SOFA Sequential organ failure assessment, VAP Ventilator-associated pneumonia, VAT Ventilator-associated tracheobronchitis
p values < 0.05 are indicated in italic characters